Arkolith/Insider Trading/INZY/Form 4

Hopfner Robert Lorne

DirectorInozyme Pharma, Inc. (INZY) · full profile →Form 4 · filed Mar 29, 2023
Net Buying
Open-Market Buys
$841K
Open-Market Sells
$0
Net Open-Market Flow
$841K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 28, 2023Buy(P)157K$4.16$652K2.9M
Mar 27, 2023Buy(P)51K$3.70$189K2.7M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-021559) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML